Source: ClinicalTrials.gov
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
View on ClinicalTrials.govCitation record
- Study start
- 2025-10-15
- NCT number
- NCT07165028
- Phase
- Phase3
- Overall status
- Recruiting
- Study type
- Interventional
- Lead sponsor
- Eli Lilly and Company
- Enrollment
- 4,500 participants
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease
- Interventions
- Tirzepatide (Drug) · Retatrutide (Drug) · Placebo (Drug)
- Last updated at source
- 8 Oct 2026
- Original source
- https://clinicaltrials.gov/study/NCT07165028
This page reproduces citation metadata only. Inclusion in the Avion Science research library does not imply endorsement and does not establish the safety, efficacy or intended use of any Avion Science compound. Refer to the original record for complete study information.